A Study for Participants With Pancreatic Cancer

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the Phase 1 portion of this study was to determine the dose of LY2603618 that can be safely administered 24 hours after gemcitabine treatment. This dose was then used for the Phase 2 portion of the study. The Phase 2 portion of the study evaluated whether LY2603618, when administered 24 hours after gemcitabine therapy, was an effective treatment for participants with pancreatic cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:

• Diagnosed with cancer that is metastatic and/or advanced during Phase 1

• Diagnosed with pancreatic cancer that is metastatic and not amenable to surgery

• Must be at least 18 years of age

• Adequate hematological, liver, and renal functions

• Eastern Cooperative Oncology Group (ECOG) status of 0 to 2

Exclusion Criteria:

• Known hypersensitivity to gemcitabine

• Pregnant or lactating females or refusal to use medically approved contraceptive precautions

• Had prior treatment with radiotherapy involving more than 25% of marrow producing area

• Have received treatment in the last 30 days with a drug which has not received regulatory approval for any indication at the time of study entry